A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate

@article{Zdravkovic2003ACS,
  title={A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate},
  author={M Jasmina Zdravkovic and Anette Kristensen Olsen and T. Christiansen and Rainer Schulz and Mitchell E. Taub and Mikael S{\o}nderg{\aa}rd Thomsen and Michael H{\o}jby Rasmussen and Mapoko M Ilondo},
  journal={European Journal of Clinical Pharmacology},
  year={2003},
  volume={58},
  pages={683-688}
}
ObjectiveNN703 (tabimorelin) is an orally active growth hormone (GH) secretagogue intended for use as an alternative to daily injections of GH. In vitro studies in human liver microsomes have indicated that NN703 is a mechanism-based inhibitor of CYP3A4. The aim of the present study was to investigate in man the effects of NN703 on the pharmacokinetics of midazolam, a substrate of CYP3A4.MethodsSeventeen adult male subjects were enrolled in the study, and each received an oral dose of midazolam… 
Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of CYP3A substrate midazolam
TLDR
Results indicate that single‐dose and repeated‐dose administration of nilotinib results in weak and moderate inhibition of CYP3A, respectively, and appropriate monitoring and dose adjustment may be needed for drugs that are mainly metabolized by CYP2A, and have narrow therapeutic index, when coadministered withnilotinib.
Investigation of the Pharmacokinetic Interactions of Deferasirox, a Once‐Daily Oral Iron Chelator, With Midazolam, Rifampin, and Repaglinide in Healthy Volunteers
TLDR
Specific patient prescribing recommendations were established when coadministering deferasirox with midazolam, repaglinide, and rifampin and these recommendations may also apply to other substrates of CYP3A4/5 and CYP2C8 or potent inducers of glucuronidation.
Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring
TLDR
To minimize drug-drug interactions involving mechanism-based CYP3A4 inhibition, it is necessary to choose safe drug combination regimens, adjust drug dosages appropriately, and conduct therapeutic drug monitoring for drugs with narrow therapeutic indices.
Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4
TLDR
A good understanding of CYP3A4 inactivation and proper clinical management are needed by clinical professionals when these drugs are used and predicting the risks for potential drug–drug interactions is needed.
Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs
TLDR
It appears that the chemical properties of a drug critical to CYP3A4 inactivation include formation of reactive metabolites by CYP isoenzymes, preponderance of CYP inducers and P-glycoprotein (P-gp) substrate, and occurrence of clinically significant pharmacokinetic interactions with coadministered drugs.
Clinical outcomes and management of mechanism-based inhibition of cytochrome P 450 3 A 4
TLDR
A good understanding of CYP3A4 inactivation and proper clinical management are needed by clinical professionals when these drugs are used and predicting the risks for potential drug–drug interactions is needed.
Static and Dynamic Projections of Drug-Drug Interactions Caused by Cytochrome P450 3A Time-Dependent Inhibitors Measured in Human Liver Microsomes and Hepatocytes
TLDR
A thorough evaluation of CYP3A TDI is reported and it is demonstrated that DDI can be predicted when using appropriate models and input parameters generated in human liver microsomes or hepatocytes.
Cytochrome P450 Inactivation by Pharmaceuticals and Phytochemicals: Therapeutic Relevance
TLDR
This review summarizes the catalytic efficiencies of many inactivator drugs along with any consequent clinical relevance and ranked the chemical agents described for the kinetic efficiency of inactivation and contrasted with the known clinically relevant drug interactions.
Cytochrome P450 3A Time-Dependent Inhibition Assays Are Too Sensitive for Identification of Drugs Causing Clinically Significant Drug-Drug Interactions: A Comparison of Human Liver Microsomes and Hepatocytes and Definition of Boundaries for Inactivation Rate Constants
TLDR
Findings offer a practical guide to the use of TDI data for CYP3A in early drug-discovery research and demonstrates suitable boundaries for inactivation rates to better delineate drug candidates for their potential to cause clinically significant drug interactions.
Physiologically-based pharmacokinetic modelling and simulation of oral drug bioavailability: Focus on bariatric surgery patients and mechanism-based inhibition of gut wall metabolism
TLDR
The aim of this thesis was to explore the interplay between oral drug absorption and metabolism occurring in the GI tract through the exploration of the impact of bariatric surgery on oral drug exposure and by theoretically examining the nesting and hierarchy of enterocyte and enzyme turnover and its impact on MBIs in the small intestine.
...
1
2
...

References

SHOWING 1-10 OF 13 REFERENCES
The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN703, a novel orally active growth hormone secretagogue in healthy male volunteers.
  • M. Zdravkovic, B. Søgaard, M. M. Ilondo
  • Medicine, Biology
    Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
  • 2000
TLDR
NN703 is a promising potential candidate for treatment of GH deficiency/insufficiency and is well tolerated by the subjects.
The area under the plasma concentration–time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin
TLDR
Switching from inhibition to induction of cytochrome P450 3A (CYP3A) enzymes causes a very great change in the AUC of oral midazolam, which is greatly decreased by itraconazole and increased by rifampicin.
Midazolam Hydroxylation by Human Liver Microsomes In Vitro: Inhibition by Fluoxetine, Norfluoxetine, and by Azole Antifungal Agents
TLDR
Results are consistent with results of other in vitro studies and of clinical studies, indicating that fluoxetine, largely via its metabolite norfluoxettine, may impair clearance of P450‐3A substrates.
In vitro and in vivo drug interactions involving human CYP3A.
TLDR
Cytochrome P4503A (CYP3A) is importantly involved in the metabolism of many chemically diverse drugs administered to humans and makes it a major contributor to presystemic elimination following oral drug administration.
Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein
TLDR
The results indicate that the overlap in substrate specificities of CYP3A and P-gp appears to be fortuitous rather than indicative of a more fundamental relationship.
Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.
TLDR
The data provide evidence that the marked interindividual variation in the response to these widely used benzodiazepine drugs is due to variable hepatic metabolism, and predominantly mediated by cytochrome P450IIIA4.
The Contribution of P‐glycoprotein to Pharmacokinetic Drug‐Drug Interactions
  • D. K. Yu
  • Biology, Medicine
    Journal of clinical pharmacology
  • 1999
TLDR
An overview of published in vitro, in situ, and in vivo drug‐drug interaction results that are related to PGP transport so that the awareness of the scientific community can be heightened.
...
1
2
...